Title : Electrophysiology and alzheimer's pathology: A scoping review on eeg correlations with CSF biomarkers
Abstract:
The increasing prevalence of Alzheimer’s Disease (AD) necessitates effective diagnostic strategies for early intervention. This presentation examines the relationship between electroencephalography (EEG) and cerebrospinal fluid (CSF) biomarkers, highlighting their combined potential to enhance diagnostic accuracy and understanding of AD pathology. EEG provides non-invasive insights into brain electrical activity, revealing changes in neural oscillations across frequency bands. Research indicates that alterations in these oscillations, particularly in delta, theta, alpha, and beta bands, correlate with the progression of Alzheimer’s disease (Babiloni et al., 2020). Concurrently, CSF biomarkers such as beta-amyloid (Aβ42) and tau proteins (total tau, t-tau; phosphorylated tau, p-tau) serve as critical indicators of neurodegenerative processes. Lower Aβ42 levels are associated with synaptic dysfunction, while elevated tau proteins indicate neurofibrillary tangles, both hallmarks of AD (Shaw et al., 2020).
This presentation synthesizes findings on the interplay between EEG parameters and CSF biomarker levels in cohorts with mild cognitive impairment (MCI) and subjective cognitive decline (SCD). Initial findings suggest that lower Aβ42 levels correlate with increased power in slower EEG frequency bands, while elevated tau levels associate with decreased power in faster bands. Integrating EEG and CSF biomarkers enhances diagnostic capabilities and deepens understanding of the neurophysiological changes associated with Alzheimer’s disease, paving the way for improved clinical outcomes and patient care.
